Skip to main content

Advertisement

SpringerLink
Log in

Richter Syndrome in Chronic Lymphocytic Leukemia

  • Chronic Lymphocytic Leukemias (N Jain, Section Editor)
  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

The term Richter syndrome (RS) indicates the transformation of chronic lymphocytic leukemia (CLL) into an aggressive lymphoma. RS is a rare complication with an aggressive clinical course, bearing an unfavorable prognosis. In the majority of cases, CLL transforms into RS as diffuse large B cell lymphoma (DLBCL), and a clonal relation between the two processes can be found. However, clonally unrelated RS can occur and transformations to other histologies beside DLBCL have been described. Recent data have shed some light on genetic characteristics that can influence and drive the transformation from CLL to RS. This molecular information has not been translated yet into significant treatment advances, and currently the therapy regimens for RS continue to rely on intensive chemotherapy combinations followed by stem cell transplant in suitable candidates. Based on the rapid pace of discoveries in the field of hematological malignancies and on the recent revolution in the therapeutic landscape for CLL and B cell lymphomas, new therapeutic options for RS might be available in the upcoming years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukemia. Am J Pathol. 1928;4(4):285–292.287.

    CAS  PubMed  PubMed Central  Google Scholar 

  2. Lortholary P, Boiron M, Ripault P, Levy JP, Manus A, Bernard J. Chronic lymphoid leukemia secondarily associated with a malignant reticulopathy: Richter’s syndrome. Nouv Rev Fr Hematol. 1964;4:621–44.

    CAS  PubMed  Google Scholar 

  3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman, JW (Eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon 2008.

  4. Choi WW, Weisenburger DD, Greiner TC, Piris MA, Banham AH, Delabie J, et al. A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(17):5494–502. doi:10.1158/1078-0432.ccr-09-0113.

    Article  CAS  Google Scholar 

  5. Rossi D, Spina V, Deambrogi C, Rasi S, Laurenti L, Stamatopoulos K, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391–401. doi:10.1182/blood-2010-09-302174. This study shows the significantly different clinical behavior of clonally related and unrelated RS.

    Article  CAS  PubMed  Google Scholar 

  6. Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, et al. IgVH mutational status and clonality analysis of Richter’s transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol. 2007;31(10):1605–14. doi:10.1097/PAS.0b013e31804bdaf8.

    Article  PubMed  Google Scholar 

  7. Tsimberidou AM, O’Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006;107(6):1294–302. doi:10.1002/cncr.22121.

    Article  CAS  PubMed  Google Scholar 

  8. Mauro FR, Foa R, Giannarelli D, Cordone I, Crescenzi S, Pescarmona E, et al. Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases. Blood. 1999;94(2):448–54.

    CAS  PubMed  Google Scholar 

  9. Tsimberidou AM, O’Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol: Off J Am Soc Clin Oncol. 2006;24(15):2343–51. doi:10.1200/jco.2005.05.0187.

    Article  CAS  Google Scholar 

  10. Rossi D, Spina V, Cerri M, Rasi S, Deambrogi C, De Paoli L, et al. Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. Clin Cancer Res: Off J Am Assoc Cancer Res. 2009;15(13):4415–22. doi:10.1158/1078-0432.ccr-08-3266.

    Article  CAS  Google Scholar 

  11. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–82. doi:10.1111/bjh.12458.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Bockorny B, Codreanu I, Dasanu CA. Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. Br J Haematol. 2012;156(1):50. doi:10.1111/j.1365-2141.2011.08907.x. This retrospective analysis summarizes the available data on the rare Hodgkin variant of RS.

    Article  PubMed  Google Scholar 

  13. Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A, et al. Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2008;142(2):202–15. doi:10.1111/j.1365-2141.2008.07166.x.

    Article  CAS  PubMed  Google Scholar 

  14. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273–88. doi:10.1084/jem.20131448. This study shows that RS genetically differs from CLL and derives from the acquisition of multiple heterogeneous new genetic lesions by the CLL clone.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chigrinova E, Rinaldi A, Kwee I, Rossi D, Rancoita PM, Strefford JC, et al. Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. Blood. 2013;122(15):2673–82. doi:10.1182/blood-2013-03-489518. This study describes two different pathways of molecular transformation from CLL to RS.

    Article  CAS  PubMed  Google Scholar 

  16. Rinaldi A, Mensah AA, Kwee I, Forconi F, Orlandi EM, Lucioni M, et al. Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. Br J Haematol. 2013;163(2):194–204. doi:10.1111/bjh.12515.

    CAS  PubMed  Google Scholar 

  17. Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Fama R, et al. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014;123(14):2139–47. doi:10.1182/blood-2013-11-539726.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Dolcetti R, Carbone A. Epstein-Barr virus infection and chronic lymphocytic leukemia: a possible progression factor? Infect Agents Cancer. 2010;5:22. doi:10.1186/1750-9378-5-22.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Solh M, Rai KR, Peterson BL, Kolitz JE, Appelbaum FR, Tallman MS, et al. The impact of initial fludarabine therapy on transformation to Richter syndrome or prolymphocytic leukemia in patients with chronic lymphocytic leukemia: analysis of an intergroup trial (CALGB 9011). Leuk Lymphoma. 2013;54(2):252–4. doi:10.3109/10428194.2012.710327.

    Article  CAS  PubMed  Google Scholar 

  20. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet. 2007;370(9583):230–9. doi:10.1016/s0140-6736(07)61125-8.

    Article  CAS  PubMed  Google Scholar 

  21. Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062–7. doi:10.1182/blood-2014-09-603670.

    Article  CAS  PubMed  Google Scholar 

  22. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1(1):80–7. doi:10.1001/jamaoncol.2014.218.

    Article  PubMed  Google Scholar 

  23. Rossi D, Spina V, Bomben R, Rasi S, Dal-Bo M, Bruscaggin A, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood. 2013;121(24):4902–5. doi:10.1182/blood-2013-02-486209.

    Article  CAS  PubMed  Google Scholar 

  24. Villamor N, Conde L, Martinez-Trillos A, Cazorla M, Navarro A, Bea S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27(5):1100–6. doi:10.1038/leu.2012.357. This study identifies the association between NOTCH1 mutation and an increased risk of transformation from CLL to RS.

    Article  CAS  PubMed  Google Scholar 

  25. Rossi D, Rasi S, Spina V, Fangazio M, Monti S, Greco M, et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol. 2012;158(3):426–9. doi:10.1111/j.1365-2141.2012.09155.x.

    Article  CAS  PubMed  Google Scholar 

  26. Rossi D, Lobetti Bodoni C, Genuardi E, Monitillo L, Drandi D, Cerri M, et al. Telomere length is an independent predictor of survival, treatment requirement and Richter’s syndrome transformation in chronic lymphocytic leukemia. Leukemia. 2009;23(6):1062–72. doi:10.1038/leu.2008.399.

    Article  CAS  PubMed  Google Scholar 

  27. Aydin S, Rossi D, Bergui L, D’Arena G, Ferrero E, Bonello L, et al. CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome? Blood. 2008;111(12):5646–53. doi:10.1182/blood-2008-01-129726.

    Article  CAS  PubMed  Google Scholar 

  28. Rasi S, Spina V, Bruscaggin A, Vaisitti T, Tripodo C, Forconi F, et al. A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol. 2011;152(3):284–94. doi:10.1111/j.1365-2141.2010.08482.x.

    Article  CAS  PubMed  Google Scholar 

  29. Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, et al. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med: Off Publ Soc Nucl Med. 2006;47(8):1267–73.

    Google Scholar 

  30. Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, et al. Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014;123(18):2783–90. doi:10.1182/blood-2013-11-536169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mauro FR, Chauvie S, Paoloni F, Biggi A, Cimino G, Rago A, et al. Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia. 2015;29(6):1360–5. doi:10.1038/leu.2015.21.

    Article  CAS  PubMed  Google Scholar 

  32. Michallet AS, Sesques P, Rabe KG, Itti E, Tordot J, Tychyj-Pinel C et al. An 18F-FDG-PET maximum standardized uptake value >10 represents a novel valid marker for discerning Richter’s Syndrome. Leuk Lymphoma. 2015;1–10. doi:10.3109/10428194.2015.1099643.

  33. Gine E, Martinez A, Villamor N, Lopez-Guillermo A, Camos M, Martinez D, et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (“accelerated” chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica. 2010;95(9):1526–33. doi:10.3324/haematol.2010.022277.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56. doi:10.1182/blood-2007-06-093906.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Kuppers R, Duhrsen U, Hansmann ML. Pathogenesis, diagnosis, and treatment of composite lymphomas. Lancet Oncol. 2014;15(10):e435–46. doi:10.1016/s1470-2045(14)70153-6.

    Article  PubMed  Google Scholar 

  36. Omoti CE, Omoti AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol. 2008;142(5):709–16. doi:10.1111/j.1365-2141.2008.07248.x.

    Article  PubMed  Google Scholar 

  37. Conte MJ, Bowen DA, Wiseman GA, Rabe KG, Slager SL, Schwager SM, et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leuk Lymphoma. 2014;55(9):2079–84. doi:10.3109/10428194.2013.869801.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch-Ginsberg C, Cork A, et al. Richter’s syndrome: a report on 39 patients. J Clin Oncol: Off J Am Soc Clin Oncol. 1993;11(10):1985–9.

    CAS  Google Scholar 

  39. Harousseau JL, Flandrin G, Tricot G, Brouet JC, Seligmann M, Bernard J. Malignant lymphoma supervening in chronic lymphocytic leukemia and related disorders. Richter’s syndrome: a study of 25 cases. Cancer. 1981;48(6):1302–8.

    Article  CAS  PubMed  Google Scholar 

  40. Langerbeins P, Busch R, Anheier N, Durig J, Bergmann M, Goebeler ME, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014;89(12):E239–43. doi:10.1002/ajh.23841.

    Article  CAS  PubMed  Google Scholar 

  41. Tadmor T, Shvidel L, Bairey O, Goldschmidt N, Ruchlemer R, Fineman R, et al. Richter’s transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study Group. Am J Hematol. 2014;89(11):E218–22. doi:10.1002/ajh.23826.

    Article  CAS  PubMed  Google Scholar 

  42. Eyre TA, Clifford R, Roberts C, Boyle L, Francis A, Schuh A, et al. Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome. BMC Cancer. 2015;15:52. doi:10.1186/s12885-015-1048-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Dabaja BS, O’Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter’s syndrome. Leuk Lymphoma. 2001;42(3):329–37. doi:10.3109/10428190109064589.

    Article  CAS  PubMed  Google Scholar 

  44. Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, et al. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003;97(7):1711–20. doi:10.1002/cncr.11238.

    Article  CAS  PubMed  Google Scholar 

  45. Tsimberidou AM, O’Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, et al. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter’s syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002;43(4):767–72. doi:10.1080/10428190290016872.

    Article  CAS  PubMed  Google Scholar 

  46. Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995;47(5):1072–9.

    CAS  PubMed  Google Scholar 

  47. Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, et al. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 1997;57(8):1487–94.

    CAS  PubMed  Google Scholar 

  48. Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992;52(4):897–903.

    CAS  PubMed  Google Scholar 

  49. Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S, et al. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol: Off J Am Soc Clin Oncol. 2008;26(2):196–203. doi:10.1200/jco.2007.11.8513.

    Article  CAS  Google Scholar 

  50. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O’Brien S, Kipps TJ, et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma, Myeloma Leuk. 2013;13(5):568–74. doi:10.1016/j.clml.2013.03.012.

    Article  CAS  Google Scholar 

  51. Durot E, Michallet AS, Lepretre S, Le QH, Leblond V, Delmer A. Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter’s syndrome: results of a French retrospective multicenter study. Eur J Haematol. 2015;95(2):160–7. doi:10.1111/ejh.12474.

    Article  CAS  PubMed  Google Scholar 

  52. Tsimberidou AM, Murray JL, O’Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer. 2004;100(10):2195–200. doi:10.1002/cncr.20252.

    Article  CAS  PubMed  Google Scholar 

  53. Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125(16):2497–506. doi:10.1182/blood-2014-10-606038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Wilson WH, Young RM, Schmitz R, Yang Y, Pittaluga S, Wright G et al. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. 2015;21(8):922–6. doi:10.1038/nm.3884.

  55. Younes A, Thieblemont C, Morschhauser F, Flinn I, Friedberg JW, Amorim S, et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol. 2014;15(9):1019–26. doi:10.1016/s1470-2045(14)70311-0.

    Article  CAS  PubMed  Google Scholar 

  56. Giri S, Hahn A, Yaghmour G, Martin MG. Ibrutinib has some activity in Richter’s syndrome. Blood Cancer J. 2015;5:e277. doi:10.1038/bcj.2014.98.

    Article  CAS  PubMed  Google Scholar 

  57. Lamar Z, Kennedy L, Kennedy B, Lynch M, Goad A, Hurd D, et al. Ibrutinib and rituximab induced rapid response in refractory Richter syndrome. Clin Case Rep. 2015;3(7):615–7. doi:10.1002/ccr3.269.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015;125(10):1676–8. doi:10.1182/blood-2014-12-610782.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Sharma RG, Call TG, Habermann TM, Ding W, Leis JF, Schwager S, et al. Outcomes of chronic lymphocytic leukemia patients with Richter syndrome. Blood. 2013;122(21):4179.

    Google Scholar 

  60. Cwynarski K, van Biezen A, de Wreede L, Stilgenbauer S, Bunjes D, Metzner B, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): a retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol: Off J Am Soc Clin Oncol. 2012;30(18):2211–7. doi:10.1200/jco.2011.37.4108.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX, 77030, USA

    Candida Vitale & Alessandra Ferrajoli

Authors
  1. Candida Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandra Ferrajoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alessandra Ferrajoli.

Ethics declarations

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Collection on Chronic Lymphocytic Leukemias

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vitale, C., Ferrajoli, A. Richter Syndrome in Chronic Lymphocytic Leukemia. Curr Hematol Malig Rep 11, 43–51 (2016). https://doi.org/10.1007/s11899-016-0300-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-016-0300-y

Keywords

Search

Navigation